197 results on '"Chu, Felix"'
Search Results
2. Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens
3. Interviewing in Educational Research: A Bibliographic Essay.
4. Supplementary Figure 5 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
5. Supplementary Figure 3 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
6. Supplementary Figure 6 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
7. Supplementary Figure Legends and Supplementary Tables 1 through 3 from Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
8. Data from Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma
9. Supplementary Information from Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma
10. Data from Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
11. Supplementary Figure 1 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
12. Supplementary Figures 1 through 5 from Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
13. Supplementary Tables 1 - 3, Figure 1 from Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
14. Data from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
15. Supplementary Figure 4 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
16. Supplementary Figure Legends, Tables 1 - 6 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
17. Supplementary Figure 2 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
18. Technocracy or transformation? Mapping women's policy agencies and orienting gender (in)equality in the Canadian provinces
19. Librarian-Faculty Relations in Collection Development.
20. Framing Reference Encounters.
21. Collaboration in a Loosely Coupled System: Librarian-Faculty Relations in Collection Development.
22. Reference Service and Bounded Rationality: Helping Students with Research.
23. Bibliographic Instruction and the Scholarship of Integration.
24. Evaluating the Skills of the Systems Librarian.
25. Framing Reference Encounters
26. 689 ATRC-101 Drives Potent Single-Agent Activity in Mouse Syngeneic Tumor Models via a Novel Cellular Mechanism of Action
27. 469 Cooperation between checkpoint inhibitors targeting the PD-1/PD-L1 axis and ATRC-101, a novel clinical-stage candidate for the treatment of solid tissue malignancies
28. Generation and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgG
29. Evaluating the skills of the systems librarian
30. Abstract 1543: Discovery of antibodies for ADC therapy from cancer patients who show durable clinical response to checkpoint inhibitors
31. Abstract 3966: Mining the cancer immuno-responsome: The identification of functional antitumor antibodies from patients receiving checkpoint inhibitors
32. Anti-tumor immune responses in metastatic breast cancer exceptional responder patients.
33. Impact on immune effectors of anti-tumor antibodies isolated from cancer patients.
34. CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis
35. The Library Is More than a Heart
36. Campbell's Call: Needed Change...
37. Free Ambience Helps Research
38. Bridging the LIS-practitioner gap: some frames for research
39. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma
40. Social aspects of information
41. Librarian-faculty relations in collection development.
42. Evaluating the Skills of a Systems Librarian.
43. Heterogeneity of cytotoxic T cell infiltration in breast and colorectal cancer
44. The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
45. Immunohistochemical Detection of FLAG-Tagged Endogenous Proteins in Knock-In Mice
46. A CD4/Foxp3/OX40 triple immunofluorescence assay determines association between T cell immune subsets and outcome in colorectal cancer
47. Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
48. In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer
49. Fluorescence Compared to Brightfield Detection of CD35 in Lymphoid Follicles of the Monkey to Assess Immunomodulatory Treatment Effect
50. Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.